Mirati Therapeutics (MRTX) Tops Q2 EPS by 13c, beats revenue
Tweet
Share
E-mail
Get Alerts MRTX Hot Sheet
Join SI Premium – FREE
Mirati Therapeutics (NASDAQ: MRTX) reported Q2 EPS of ($3.04), $0.13 better than the analyst estimate of ($3.17). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $13.19 million.
For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CoreWeave, Inc. (CRWV) Tops Q2 EPS by 27c
- Quicklogic Corp (QUIK) Misses Q2 EPS by 2c
- LENZ Therapeutics, Inc. (LENZ) Tops Q2 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
